Ocean Biomedical, Inc. (OCEA) Cash Flow Statement
Where OCEA’s cash came from and went, 2024
December 31, 2024 · U.S. dollars- Cash from operations
- −$4.2M
- Capital expenditures
- $0
- Free cash flow
- −$4.2M
- Returned to shareholders
- —
- Change in cash
- −$780,000 cash at year-end $224,000
Drawn to scale: where the cash came from and how it was used. Hover for values.
OCEA operating cash flow, capex and free cash flow
OCEA cash flow trends, 2019–2024
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$64,0002019 | −$4.2M2024 | — | |
| Capital expenditures | $02019 | $02024 | — | |
| Free cash flow | $02019 | −$4.2M2024 | — | |
| Stock-based compensation | $02020 | $745,0002024 | — | |
| Share buybacks (net) | $02022 | $02024 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
OCEA cash flow by activity
OCEA net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
OCEA cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Operating activities | ||||||
| Net income | −$9.5M | −$114.5M | −$958,430 | −$62.3M | −$1.7M | −$232,000 |
| Stock-based compensation | $745,000 | $1.2M | $12.4M | $56.5M | $0 | — |
| Change in working capital | $1.0M | $1.2M | $1.7M | $4.7M | $1.6M | $232,000 |
| Other non-cash items | $3.5M | $102.7M | −$13.9M | $0 | $0 | −$64,000 |
| Cash from operating activities | −$4.2M | −$9.4M | −$747,297 | −$1.1M | −$64,000 | −$64,000 |
| Investing activities | ||||||
| Capital expenditures | $0 | $0 | −$3 | $0 | $0 | $0 |
| Investments (net) | — | — | −$2.1M | $0 | $0 | $0 |
| Acquisitions & other investing | — | — | $3 | −$107.1M | — | — |
| Cash from investing activities | — | — | −$2.1M | −$107.1M | — | — |
| Financing activities | ||||||
| Share repurchases & issuance (net) | $0 | −$64.3M | $0 | — | — | — |
| Net borrowing (repayment) | $3.4M | $6.8M | $735,000 | — | — | — |
| Shares issued | $0 | $15.8M | $0 | $1.0M | $0 | $0 |
| Other financing | $0 | $52.1M | $1.4M | $96,000 | $64,000 | $64,000 |
| Cash from financing activities | $3.4M | $10.4M | $2.1M | $1.1M | $64,000 | $64,000 |
| Summary | ||||||
| Net change in cash | −$780,000 | $970,000 | −$747,297 | $60,000 | $64,000 | $60,000 |
| Cash at end of period | $224,000 | $1.0M | $328,305 | $60,000 | $107.1M | $0 |
| Free cash flow | −$4.2M | −$9.4M | −$747,300 | −$1.1M | −$64,000 | $0 |
| Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$8.2M | $283,000 | −$5.5M | −$17.2M | $13.0M | −$16.9M | −$14.1M | −$13.0M | −$67.4M | $410,050 | −$1.0M | −$7.3M |
| Stock-based compensation | $186,000 | $186,000 | $186,000 | $373,000 | $186,000 | $187,000 | $186,000 | $186,000 | $646,000 | — | $2.9M | $4.9M |
| Change in working capital | $759,000 | −$520,000 | $235,000 | $767,000 | $561,000 | −$1.2M | $1.6M | −$1.4M | $1.9M | $471,069 | $1.1M | $2.2M |
| Other non-cash items | $6.9M | −$2.5M | $4.2M | $15.8M | −$14.2M | $17.0M | $11.2M | $9.5M | $62.2M | −$1.0M | −$3.3M | $115,000 |
| Cash from operating activities | −$356,000 | −$2.5M | −$885,000 | −$290,000 | −$485,000 | −$866,000 | −$1.1M | −$4.8M | −$2.7M | −$143,800 | −$313,789 | −$152,000 |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Acquisitions & other investing | — | — | — | — | — | — | — | — | — | −$1.1M | −$1.1M | — |
| Cash from investing activities | — | — | — | — | — | — | — | — | — | −$1.1M | −$1.1M | — |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | $0 | $0 | $0 | $0 | $0 | −$51.6M | $0 | −$12.7M | — | $0 | — |
| Net borrowing (repayment) | $909,000 | $2.5M | $896,000 | $0 | $0 | — | — | $5.2M | $5.2M | $5.2M | — | $165,000 |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $52.1M | $14.3M | $0 | $0 | $0 |
| Other financing | $0 | $0 | $0 | $0 | $0 | $839,000 | $51.6M | −$50.6M | −$3.9M | −$4.1M | $1.3M | $90,000 |
| Cash from financing activities | $909,000 | $2.5M | $896,000 | $0 | $0 | $839,000 | $0 | $6.6M | $2.9M | $1.1M | $1.3M | $255,000 |
| Summary | ||||||||||||
| Net change in cash | $553,000 | −$16,000 | $11,000 | −$290,000 | −$485,000 | −$27,000 | −$1.1M | $1.9M | $272,000 | −$143,800 | −$104,654 | $103,000 |
| Cash at end of period | $777,000 | $224,000 | $240,000 | $229,000 | $519,000 | $1.0M | $1.0M | $2.2M | $306,000 | $328,305 | $472,105 | $395,000 |
| Free cash flow | −$356,000 | −$2.5M | −$885,000 | −$290,000 | −$485,000 | −$866,000 | −$1.1M | −$4.8M | −$2.7M | −$143,800 | −$313,789 | −$152,000 |
| Operating cash flow / net income | — | −8.90 | — | — | −0.04 | — | — | — | — | −0.35 | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
OCEA cash generation
In fiscal 2024 (ended December 31, 2024), Ocean Biomedical generated -$4.2 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$4.2 million. Cash and equivalents fell by $0.8 million over the year.
Related: OCEA income statement, OCEA balance sheet. See the OCEA stock overview for the latest quote and news.
OCEA cash flow FAQ
What is Ocean Biomedical's free cash flow?
Ocean Biomedical's free cash flow was -$4.2 million in fiscal 2024: -$4.2 million of operating cash flow minus $0 of capital expenditures It was -$9.4 million a year earlier..
How much cash does Ocean Biomedical generate from operations?
Ocean Biomedical generated -$4.2 million of cash from operating activities in fiscal 2024.